Daprodustat for Anaemia in Patients with Heart Failure and Chronic Kidney Disease: A Randomized Controlled Study
Open Access
- 18 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (6) , 4291-4297
Abstract
Aims: Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors have been developed for the treatment of renal anaemia; however, no study has evaluated the safety and efficacy of HIF-PH inhibitors in patients with heart failure (HF). This study was designed to evaluate the safety and efficacy of daprodustat, a HIF-PH inhibitor, in patients with HF and renal anaemia. Methods and results: We designed a pilot, multi-centre, open-label, randomized controlled study, in which 50 patients with HF complicated with chronic kidney disease and anaemia will be randomized 1:1 to either the daprodustat or control group at seven sites in Japan. Study entry requires New York Heart Association Class II HF symptoms or a history of hospitalization due to HF, an estimated glomerular filtration rate of <60 mL/min/1.73 m2, and a haemoglobin level of 7.5 to <11.0 g/dl. Patients randomized to the daprodustat group will be treated with oral daprodustat, and the dose will be uptitrated according to the changes in the haemoglobin level from previous visits. In this study, we will evaluate the impact of HIF-PH inhibitors on cardiac function using advanced cardiovascular imaging modalities, including cardiac magnetic resonance imaging. The primary outcome is the haemoglobin level at 16 weeks of randomization, and all adverse events will be recorded and evaluated for any association with daprodustat treatment. Conclusion: Considering the hypothetical upside and downside of using HIF-PH inhibitors in anaemic patients with HF and chronic kidney disease, and because there are virtually no safe and effective treatments for patients with anaemia not caused by iron deficiency, our study results will contribute significantly to this field.Keywords
This publication has 38 references indexed in Scilit:
- Treatment of Anemia with Darbepoetin Alfa in Systolic Heart FailureNew England Journal of Medicine, 2013
- Shortened Red Blood Cell Lifespan Is Related to the Dose of Erythropoiesis‐Stimulating Agents Requirement in Patients on HemodialysisTherapeutic Apheresis and Dialysis, 2012
- Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic CardiomyopathyCirculation, 2010
- Hypoxia inducible factor 1 (HIF-1) and cardioprotectionActa Pharmacologica Sinica, 2010
- Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomesKidney International, 2008
- Anemia and Chronic Heart FailureJACC, 2008
- Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and AnemiaCirculation, 2008
- p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overloadNature, 2007
- Hypoxia-Inducible Factor 1-Alpha Reduces Infarction and Attenuates Progression of Cardiac Dysfunction After Myocardial Infarction in the MouseJACC, 2005
- Abnormal Cutaneous Topobiology: The Molecular Basis for Dermatopathologic Mononuclear Cell Patterns in Inflammatory Skin DiseaseJournal of Investigative Dermatology, 1990